UNSPSC 51313502: Barmastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C27H29N7O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UIF43N1HSV, chemically known as 4h-pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-((3-(2-furanylmethyl)-3h-imidazo(4,5-b)pyridin-2-yl)amino)-1-piperidinyl)ethyl)-2-methyl-;(2) 3-(2-(4-((3-furfuryl-3h-imidazo(4,5-b)pyridin-2-yl)amino)piperidino)ethyl)-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one but generally known as barmastine, which bears US NIH Compound Identifier 71300.

UNSPSC 51313502 Barmastine, a Commodity code, covers naloxone, drug deactivation systems, and pharmaceutical products supplied to state and local health agencies, community health departments, and multistate cooperative purchasing organizations. State and local governments buy these products for emergency medical response, substance-abuse intervention, and pharmacy benefit programs serving public employees and beneficiaries. Issuing bodies include county health departments, state health and human services commissions, and regional cooperative purchasing alliances administering contracts on behalf of multiple participating jurisdictions. Naloxone and drug deactivation systems are procured through competitive bidding (IFB) for quarterly delivery to county health facilities; generic pharmaceuticals and OTC products are procured through RFPs issued by multistate cooperatives and administered by state procurement offices, with awards made to multiple manufacturers based on price competitiveness, product availability, and compliance with manufacturing and supply-chain security standards.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting with manufacturers outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026, and an effective contract date of July 1, 2026. All three procurements require vendors to meet federal manufacturing and compliance standards, maintain specified insurance coverage, and commit to transparent pricing and performance accountability.